Vipivotide tetraxetan

Vipivotide tetraxetan
Clinical data
Other names	PSMA-617
Identifiers
	IUPAC name (2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid;
CAS Number	1702967-37-0;
PubChem CID	122706786;
ChemSpider	72380176;
UNII	4YM1W0EGQ5;
KEGG	D11697;
ChEMBL	ChEMBL4594280;
PDB ligand	QYF (PDBe, RCSB PDB);
Chemical and physical data
Formula	C49H71N9O16
Molar mass	1042.154 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O;
	InChI InChI=InChI=1S/C49H71N9O16/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74)/t32?,35?,37-,38-,39-/m0/s1; Key:JBHPLHATEXGMQR-VLOIPPKDSA-N;

Vipivotide tetraxetan (also known as PSMA-617) is a radiopharmaceutical precursor molecule used in targeted therapies for prostate cancer and other tumors expressing prostate-specific membrane antigen (PSMA).

PSMA-617 is a high-affinity inhibitor of the peptidase activity of PSMA, with a K_i of 0.37 nM. It consists of a PSMA-targeting moiety conjugated to a high-affinity chelator for metal isotopes.^[1] Its strong binding affinity for PSMA allows precise targeting of cancer cells that overexpress this protein, especially in prostate cancer.

Vipivotide tetraxetan is used as a precursor in the synthesis of radiopharmaceuticals such as Lu-PSMA-617 and Ac-PSMA-617.^[2] In Lu-PSMA-617, vipivotide tetraxetan chelates the radioactive isotope lutetium-177, a β-emitter used in targeted radioligand therapy. In Ac-PSMA-617, it binds actinium-225, an α-emitter used in targeted alpha-particle therapy.

^ Schäfer M, Bauder-Wüst U, Roscher M, Motlová L, Kutilová Z, Remde Y, et al. (February 2025). "Structure-Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions". ACS Omega. 10 (7): 7077–7090. doi:10.1021/acsomega.4c10142. PMC 11865982. PMID 40028088.
^ Ma J, Li L, Liao T, Gong W, Zhang C (2022). "Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis". Frontiers in Oncology. 12: 796657. doi:10.3389/fonc.2022.796657. PMC 8852230. PMID 35186737.

[Schäfer_2025-1] Schäfer M, Bauder-Wüst U, Roscher M, Motlová L, Kutilová Z, Remde Y, et al. (February 2025). "Structure-Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions". ACS Omega. 10 (7): 7077–7090. doi:10.1021/acsomega.4c10142. PMC 11865982. PMID 40028088.

[Ma_2022-2] Ma J, Li L, Liao T, Gong W, Zhang C (2022). "Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis". Frontiers in Oncology. 12: 796657. doi:10.3389/fonc.2022.796657. PMC 8852230. PMID 35186737.

[1]

[2]